| Name | PF-04634817 |
|---|
| Description | PF-0463481, an oral CCR2/5 dual antagonist, with a favorable ocular safety profile versus intravitreal therapies[1]. PF-0463481 is safe and well-tolerated and being developed for the treatment of diabetic nephropathy[2]. |
|---|---|
| Related Catalog | |
| Target |
CCR2 CCR5 |
| References |
| Molecular Formula | C25H36F3N5O3 |
|---|---|
| Molecular Weight | 511.58 |